

spoc cells, that can be induced, either *in vivo* or *in vitro*, to differentiate into cardiomyocytes. Spoc cells may be differentiated and utilized for screening agents that affect cardiomyocytes and as therapeutic agents in the treatment of myocardial defects.

Maxp1

Geoffrey J. Clark, Michelle Vos (NCI); DHHS Reference No. E-165-01/0 filed September 19, 2001.

Licensing Contact: Matthew Kiser; 301/496-7056 ext. 224; e-mail: kiserm@od.nih.gov.

The subject invention is directed to the cDNA sequence and the deduced amino acid sequence of the human Maxp1 gene. Maxp1 is frequently down-regulated in primary human tumors. Accordingly, a vector comprising the cDNA sequence, a host cell comprising such a vector, a method of using the vector, such as one comprising a cDNA sequence in which the C-terminal Ras binding site has been mutated or deleted, or the polypeptide (or fragment thereof, such as one in which the C-terminal Ras binding site has been mutated or deleted) in the prophylactic and therapeutic treatment of cancer, a method of assaying small molecules for the ability to stimulate Maxp1 growth inhibitory function in cancer cells that remain positive for Maxp1 expression, and the assessment of the levels of Maxp1 mRNA or protein in the diagnosis, characterization and prognosis of cancer are additional, non-limiting embodiments of the invention.

Further embodiments include: (a) Diagnosis and prediction of tumor characteristics, (b) gene therapy to restore Nore1/Maxp1 function in tumor cells which have lost protein expression, (c) the use of small molecules to simulate Nore1/Maxp1 growth inhibitory function in tumor cells which remain positive for Nore1/Maxp1 expression, (d) the use of protein fragments/small molecules based on Nore1/Maxp1 structure to bind and inhibit the function of mutant Ras oncoproteins, and (e) a specific polyclonal antibody that works in westerns and in immunohistochemistry.

Dated: August 22, 2002.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 02-22077 Filed 8-28-02; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Cancellation of Meeting

Notice is hereby given of the cancellation of the National Cancer Institute Director's Consumer Liaison Group, September 5, 2002, 2 p.m. to September 5, 2002, 4 p.m., 6116 Executive Blvd, Rockville, MD, 20852 which was published in the **Federal Register** on August 16, 2002, 67FR535392.

The meeting is cancelled due to scheduling conflicts.

Dated: August 22, 2002.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 02-22061 Filed 8-28-02; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel, Spore in Lung Cancer.

Date: October 3-4, 2002.

Time: 8 a.m. to 6 p.m.

Agenda: To review and evaluate grant applications.

Place: Washington Terrace Hotel, 1515 Rhode Island Avenue, NW., Washington, DC 20005.

Contact Person: Brian E. Wojcik, Ph.D., Scientific Review Administrator, Grants Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Boulevard, Room 8019, Bethesda, MD 20892, 301/402-2785.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction;

93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support, 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: August 22, 2002.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 02-22064 Filed 8-28-02; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the meeting of the President's Cancer Panel.

The meeting will be closed to the public in accordance with the provisions set forth in section 552b(c)(9)(B), Title 5 U.S.C., as amended because the premature disclosure of information and the discussions would likely to significantly frustrate implementation of recommendations.

Name of Committee: President's Cancer Panel.

Date: September 16, 2002.

Closed: 2 p.m. to 6 p.m.

Agenda: Meeting with Panel, two of which are new Members, to review the previous year's activities of the Panel and develop agendas for future meetings in 2003. These discussions will include confidential NCI operational information, i.e. budget formulations, personnel actions and contract issuances.

Place: National Institutes of Health, 31 Center Drive, Building 31, Room 31/11A10, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Maureen O. Wilson, Ph.D., Executive Secretary, National Cancer Institute, NIH, 31 Center Drive, Building 31, Room 3A18, Bethesda, MD 20892, (301) 496-1148.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: deainfo.nci.nih.gov/advisory/pcp/pcp.htm, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction;